262 related articles for article (PubMed ID: 36621626)
1. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins.
Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X
J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
6. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
7. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
8. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
9. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
10. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
12. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
13. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
14. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
16. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.
Zhang L; Lopez H; George NM; Liu X; Pang X; Luo X
Cell Death Differ; 2011 May; 18(5):864-73. PubMed ID: 21113147
[TBL] [Abstract][Full Text] [Related]
17. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
18. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract][Full Text] [Related]
19. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
